Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07807475) titled 'DNP-MRSI of HCC Metabolism to Predict Therapeutic Response' on Sept. 2.
Study Type: Observational
Primary Sponsor: Abramson Cancer Center at Penn Medicine
Condition:
Barcelona Clinic Liver Cancer (BCLC) Stage A, B or C HCC
Intervention:
Drug: Hyperpolarized 1-13C -Pyruvate
Recruitment Status: Not recruiting
Date of First Enrollment: September 15, 2026
Target Sample Size: 232
To know more, visit https://clinicaltrials.gov/study/NCT07807475
Disclaimer: Curated by HT Syndication....